Who are Ibuprofen Acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytotec, alpha-blocker and NSAID, Ketorolac Ophthalmic Solution, Non-selective NSAIDS, DICL-SR, Bromfenac Sodium 0.07%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibuprofen-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ibuprofen Acid — Competitive Intelligence Brief

Ibuprofen Acid (Ibuprofen Acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Inflammation.

marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Pain Management, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Ibuprofen Acid (Ibuprofen Acid) — Reckitt Benckiser Healthcare (UK) Limited. Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ibuprofen Acid TARGET	Ibuprofen Acid	Reckitt Benckiser Healthcare (UK) Limited	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
alpha-blocker and NSAID	alpha-blocker and NSAID	Samsung Medical Center	marketed	Alpha-blocker and NSAID combination	Alpha-1 adrenergic receptor; COX-1 and COX-2 enzymes
Ketorolac Ophthalmic Solution	Ketorolac Ophthalmic Solution	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Non-selective NSAIDS	Non-selective NSAIDS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Non-selective NSAID	COX-1 and COX-2
DICL-SR	DICL-SR	Kunming Baker Norton Pharmaceutical Sales Co., Ltd.	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2
Bromfenac Sodium 0.07%	Bromfenac Sodium 0.07%	Retina Research Institute, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

Università degli Studi di Brescia · 4 drugs in this class
Bausch & Lomb Incorporated · 4 drugs in this class
Bayer · 3 drugs in this class
Pfizer · 3 drugs in this class
Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
Organon and Co · 3 drugs in this class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
Bezmialem Vakif University · 2 drugs in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibuprofen Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-acid. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab